Is inverse probability of censoring weighting a safer choice than per-protocol analysis in clinical trials?

Autor: Xuan J; MRC Clinical Trials Unit at UCL, University College London, London, UK., Mt-Isa S; Biostatistics and Research Decision Sciences (BARDS) Health Technology Assessment (HTA) Statistics, MSD, Zurich, Switzerland., Latimer N; Sheffield Centre for Health and Related Research, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.; Delta Hat Limited, Nottingham, UK., Bell Gorrod H; Sheffield Centre for Health and Related Research, School of Medicine and Population Health, University of Sheffield, Sheffield, UK., Malbecq W; Department of Mathematics, University of Brussels, Brussels, Belgium.; Former employee of MSD, Brussels, Belgium throughout most of the duration of this study., Vandormael K; Biostatistics and Research Decision Sciences (BARDS) Health Technology Assessment (HTA) Statistics, MSD, Brussels, Belgium., Yorke-Edwards V; MRC Clinical Trials Unit at UCL, University College London, London, UK.; Centre for Advanced Research Computing, University College London, London, UK., White IR; MRC Clinical Trials Unit at UCL, University College London, London, UK.

Publikováno v: Statistical methods in medical research [Stat Methods Med Res] 2024 Dec 12, pp. 9622802241289559. Date of Electronic Publication: 2024 Dec 12.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

MO01.18 An indirect Comparison of Pembrolizumab+Chemo vs Ipilimumab+Nivolumab as First-Line Therapies in Patients with PD-L1 TPS≥1% Metastatic NSCLC

Autor: Halmos, B., Burke, T., Kalyvas, C., Insinga, R., Vandormael, K., Frederickson, A., Piperdi, B.

Publikováno v: In Journal of Thoracic Oncology January 2021 16(1) Supplement:S23-S23

Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.

Autor: Halmos B; Department of Oncology, Montefiore/Albert Einstein Cancer Center, 2nd Floor, 1695 Eastchester Rd, Bronx, NY, 10461, USA. Electronic address: bahalmos@montefiore.org., Burke T; Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, 07033, USA. Electronic address: thomas_burke2@merck.com., Kalyvas C; Biostatistics and Research Decision Sciences, MSD Europe, Inc., Brussels, 1200, Belgium. Electronic address: chrysostomos.kalyvas@merck.com., Vandormael K; Biostatistics and Research Decision Sciences, MSD Europe, Inc., Brussels, 1200, Belgium. Electronic address: kristel_vandormael@merck.com., Frederickson A; precisionHEOR, Oakland, CA, 94612, USA. Electronic address: andrew.frederickson@precisionvh.com., Piperdi B; Oncology Clinical Development, Merck & Co., Inc., Kenilworth, NJ, 07033, USA. Electronic address: bilal.piperdi@merck.com.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2021 May; Vol. 155, pp. 175-182. Date of Electronic Publication: 2021 Mar 30.